Eyenovia, Inc. (EYEN)
| Previous close | 0.7113 |
| Open | 0.7580 |
| Bid | 0.5940 x 400 |
| Ask | 0.6140 x 400 |
| Day's range | 0.5964 - 0.7590 |
| 52-week range | 0.5010 - 5.8500 |
| Volume | |
| Avg. volume | 1,279,296 |
| Market cap | 28.854M |
| Beta (5Y monthly) | 1.66 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6600 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.07 |
GlobeNewswireEyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO presentation on the unique technology behind clobetasol that allows for future ophthalmic suspensions to be dispensed with the Optejet® NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved produ
ZacksEyenovia (EYEN) Down 18% on Disappointing Corporate Update
Eyenovia (EYEN) plunges 18% after sharing plans to consider strategic alternatives involving the sale of the company or assets, amid a severe cash crunch and poor performance of marketed drugs.
- GlobeNewswire
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in 2025Continuing to advance commercialization of Mydcombi for mydriasis and preparing to launch clobetasol propionate ophthalmic suspension 0.05% for post-surgical management of pain and inflammation; both represent large multi-million-dollar opportunitiesCompany exploring wide range of strategic alternatives NEW
